MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Europe
*Europe: Regions
*Western Europe
Ireland
*Industry: Ireland
Celgene (NASDAQ: CELG)
Finance & Acquisitions: Celgene
Juno Therapeutics (JUNO)
Organization & Developments: Juno Therapeutics
Parents
Juno Therapeutics (JUNO)
Children
2015: Biotech’s Coming Cancer Cure_CAR-T
2015: Juno Therapeutics Gets Lift From Cancer Test Results
2015: Juno-Celgene Deal Has Street Cautiously Optimistic CELG JUNO BLUE
2016: And Just Like That, Juno Therapeutics Is Back in Business
2016: Deaths in Immune-Therapy Trials Haunt Promising New Cancer Treatment
2016: Juno slammed on suspension of mid-stage study of lead product candidate JCAR015; shares down 28% premarket - Juno Therapeutics (NASDAQ:JUNO)
2016: Juno Therapeutics Falls After Correcting Number Of Trial Deaths
2016: Seattle-based Juno is paying $25 million upfront and another $22 million over five years to license Crispr to genetically engineer cells that can recognize and kill cancer cells.
2016: UPDATED: FDA halts Juno CAR-T trial after three patient deaths
2017: Juno ditches lead CAR-T program following patient deaths
a joint venture between Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children's Research Institute
CAR-T cell immunotherapy
Leukemia Drug
Jumps
*Key People: Juno Therapeutics
Finance & Acquisitions: Juno Therapeutics